<SEC-DOCUMENT>0001213900-26-025464.txt : 20260310
<SEC-HEADER>0001213900-26-025464.hdr.sgml : 20260310
<ACCEPTANCE-DATETIME>20260310091134
ACCESSION NUMBER:		0001213900-26-025464
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260310
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260310
DATE AS OF CHANGE:		20260310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CITIUS ONCOLOGY, INC.
		CENTRAL INDEX KEY:			0001851484
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				994362660
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41534
		FILM NUMBER:		26737444

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6677

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		FIRST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TenX Keane Acquisition
		DATE OF NAME CHANGE:	20210315
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0280663-8k_citius.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:CTOR="http://citiusonc.com/20260310">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_CTOR_citiusonc.com_20260310 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20260310_20260310 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001851484 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000004" name="dei:EntityCentralIndexKey">0001851484</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ctor-20260310.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-03-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001851484</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-10</xbrli:startDate>
        <xbrli:endDate>2026-03-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90A_edei--DocumentType_c20260310__20260310_zwnjnlbUxHJ"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">the Securities Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported)
<b><span style="text-decoration: underline"><span id="xdx_90A_edei--DocumentPeriodEndDate_c20260310__20260310_zfLDVUiJcMxh"><ix:nonNumeric contextRef="AsOf2026-03-10" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">March 10, 2026</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityRegistrantName_c20260310__20260310_zpu5SNnGjLo7"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000011" name="dei:EntityRegistrantName">Citius Oncology, Inc.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20260310__20260310_ztY1Bw052Sse"><ix:nonNumeric contextRef="AsOf2026-03-10" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityFileNumber_c20260310__20260310_zMjVI1kGtmg5"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000013" name="dei:EntityFileNumber">001-41534</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20260310__20260310_zto5hFIODJhh"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000014" name="dei:EntityTaxIdentificationNumber">99-4362660</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer <br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20260310__20260310_zJ2fJx8h1Rmj"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000015" name="dei:EntityAddressAddressLine1">11 Commerce Drive</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20260310__20260310_zZGRxCzt90b1"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000016" name="dei:EntityAddressAddressLine2">1st Floor</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressCityOrTown_c20260310__20260310_zrGsncw0IZFk"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000017" name="dei:EntityAddressCityOrTown">Cranford</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20260310__20260310_z7DOeixKtf8i"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000018" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressPostalZipCode_c20260310__20260310_z6hA5clvPN8l"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000019" name="dei:EntityAddressPostalZipCode">07016</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code <b><span style="text-decoration: underline">(<span id="xdx_900_edei--CityAreaCode_c20260310__20260310_zIWNBuwcSH8k"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000020" name="dei:CityAreaCode">908</ix:nonNumeric></span>) <span id="xdx_900_edei--LocalPhoneNumber_c20260310__20260310_z7McnFkM0FB4"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000021" name="dei:LocalPhoneNumber">967-6677</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--WrittenCommunications_c20260310__20260310_zb0dujBme7Ll"><ix:nonNumeric contextRef="AsOf2026-03-10" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--SolicitingMaterial_c20260310__20260310_zt4SeoKyhcm7"><ix:nonNumeric contextRef="AsOf2026-03-10" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementTenderOffer_c20260310__20260310_zmo99JYrWice"><ix:nonNumeric contextRef="AsOf2026-03-10" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20260310__20260310_zvMJWhnIB524"><ix:nonNumeric contextRef="AsOf2026-03-10" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--Security12bTitle_c20260310__20260310_z2fe1CVRVyE9"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000026" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--TradingSymbol_c20260310__20260310_z4dlWpmo8uw3"><ix:nonNumeric contextRef="AsOf2026-03-10" id="Fact000027" name="dei:TradingSymbol">CTOR</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>The <span id="xdx_909_edei--SecurityExchangeName_c20260310__20260310_zogExndDWsX5"><ix:nonNumeric contextRef="AsOf2026-03-10" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20260310__20260310_z8LvW1ZX2Ebe"><ix:nonNumeric contextRef="AsOf2026-03-10" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityExTransitionPeriod_c20260310__20260310_zf3udDdXOEqe"><ix:nonNumeric contextRef="AsOf2026-03-10" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-indent: -58.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 10, 2026, we issued a press release announcing
positive topline results from a completed investigator-initiated Phase&#8239;1 clinical trial conducted by University of Pittsburgh investigators.
This study evaluated the direct T-regulatory (Treg) cell depletion activity of LYMPHIR&#8482; (denileukin diftitox-cxdl) in combination
with the PD-1 immune checkpoint inhibitor pembrolizumab (KEYTRUDA<sup>&#174;</sup>) in patients with recurrent or refractory gynecologic
cancers, including ovarian and endometrial malignancies. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-size: 10pt">Exhibit No.</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-size: 10pt">Description</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td><a href="ea028066301ex99-1.htm"><span style="font-size: 10pt">Press release, dated March 10, 2026.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 40%"><span style="font-size: 10pt"><b>CITIUS ONCOLOGY, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: March 10, 2026</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Leonard Mazur</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Leonard Mazur</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chairman and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6LdrNH3CXjiniFBki3haXSXFrRlrnfCTf0rohhkBIzvlyhBiJDa11hQyXVZ7BCeumUg4hxxIZzRW9I9nuYvAzx5u2jpVx/foDE/IMemYxnil/752ttljEIKcTuZxEC5DzWC7huBfBV0/IlLpA47SqQJkCjkwNa3SKX8OHk+rIUP3qk87IVpOJIRzLQX5DJMMIDtSqJ/HdQpYlIhj1FYgN06PxrrRzaL4kpBXWPs4O9L+DD9DlSmU= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea028066301ex99-1.htm
<DESCRIPTION>PRESS RELEASE, DATED MARCH 10, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea028066301_ex99-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Citius Oncology Announces Positive Topline Results
from Investigator-Initiated Phase 1 Study of LYMPHIR&trade; in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Study data from patients with relapsed or refractory
gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Topline data of University of Pittsburgh-led
trial to be presented at an upcoming international cancer conference later this year</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CRANFORD, N.J.</B>, March 10, 2026 &ndash;
Citius Oncology, Inc. (&ldquo;Citius Oncology&rdquo;) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned
subsidiary of Citius Pharmaceuticals, Inc. (&ldquo;Citius Pharma&rdquo;) (Nasdaq: CTXR), today announced positive topline results from
a completed investigator-initiated Phase&#8239;1 clinical trial conducted by University of Pittsburgh investigators. This study evaluated
the direct T-regulatory (Treg) cell depletion activity of LYMPHIR&trade; (denileukin diftitox-cxdl) in combination with the PD-1 immune
checkpoint inhibitor pembrolizumab (KEYTRUDA<SUP>&reg;</SUP>) in patients with recurrent or refractory gynecologic cancers, including
ovarian and endometrial malignancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patients with relapsed or refractory gynecological
cancer have poor prognoses and very limited treatment options. This dose-escalation Phase 1 non-chemotherapy based clinical study aimed
to establish a recommended dose of LYMPHIR in combination with pembrolizumab for a Phase 2 study. In 25 evaluable patients, no unexpected
safety signals or serious immune-related adverse events were observed at any dose level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are encouraged by the favorable safety
profile and sustained disease control observed in this heavily pretreated patient population. Evidence from the study suggests augmented
anti-tumor activity when LYMPHIR is combined with KEYTRUDA and warrants further exploration in Phase&#8239;2 settings,&rdquo; stated Dr.
Myron Czuczman, Executive Vice President and Chief Medical Officer of Citius Oncology and Citius Pharma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trial explored efficacy and demonstrated a
24&#8239;% objective response rate (ORR) and a 48&#8239;% clinical benefit rate (CBR, defined as complete response, partial response and/or
stable disease for six months or greater) among 21 evaluable patients. Full safety and clinical efficacy results are expected to be presented
at an international cancer conference later this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;The efficacy signal shown by this combination
is incredibly exciting considering the minimal impact immuno-oncology has made in ovarian cancer thus far. If these findings are confirmed
in subsequent studies, we may have a transformational therapy on our hands,&rdquo; said Dr. Alexander Olawaiye, principal investigator
of the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About the Study</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This open-label, dose-escalation, investigator-initiated
Phase&#8239;1 study (NCT05200559), led by Dr. Alexander B Olawaiye at UPMC Magee-Women&rsquo;s Hospital, enrolled patients with recurrent
or metastatic solid tumors who had received at least one prior line of therapy. LYMPHIR was administered intravenously on Days&#8239;1&ndash;3
of each 21-day cycle at escalating doses (3, 6, 9, and 12 mcg/kg), along with pembrolizumab (200&#8239;mg IV) on Day&#8239;1. Patients
who completed eight cycles of combination therapy were continued on pembrolizumab monotherapy until disease progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The use of LYMPHIR in this study was investigational
and outside of its FDA-approved indication. The Phase 1 study was not designed or powered to evaluate clinical efficacy, and no conclusions
can be drawn regarding comparative effectiveness or long-term outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Gynecologic Cancers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recurrent or metastatic ovarian and endometrial
cancers are two of the most common gynecologic malignancies in the United States. Endometrial cancer is the most frequently diagnosed
gynecologic cancer, with an estimated 70,000 new cases expected in 2026<SUP>1</SUP>, while ovarian cancer remains the deadliest with approximately
12,700 deaths per year (51.6% 5 year survival) and approximately 20,000 new diagnoses each year<SUP>2</SUP>. These cancers are often detected
at advanced stages, and although many patients initially respond to platinum-based chemotherapy, most experience relapse and develop resistance.
Survival rates in the recurrent setting remain poor, and responses to current immunotherapies such as PD-1 inhibitors are limited, highlighting
a significant unmet need for novel treatment approaches. LYMPHIR&rsquo;s transient depletion of regulatory T-cells may enhance anti-tumor
immune responses and help overcome immunotherapy resistance in these difficult-to-treat tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About LYMPHIR&trade; (denileukin diftitox-cxdl)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LYMPHIR is a targeted immune therapy for relapsed
or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It
is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically
binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis.
After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin
diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a
direct cytocidal action on IL-2R-expressing tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2021, denileukin diftitox received regulatory
approval in Japan for the treatment of relapsed or refractory CTCL and peripheral T-cell lymphoma (PTCL). Subsequently, in 2021, Citius
acquired an exclusive license with rights to develop and commercialize denileukin diftitox in all markets except for India, Japan and
certain parts of Asia. LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Citius Oncology, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Citius Oncology, Inc. (Nasdaq: CTOR) is a platform
to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA
for the treatment of adults with relapsed or refractory Stage I&ndash;III CTCL who had had at least one prior systemic therapy. Management
estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust
intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology
use as a combination therapy with checkpoint inhibitors would further support Citius Oncology&rsquo;s competitive positioning. For more
information, please visit www.citiusonc.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these
statements by the fact that they use words such as &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;plan,&rdquo; &ldquo;should,&rdquo; and &ldquo;may&rdquo; and other words and terms of similar meaning or use of future dates. Forward-looking
statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those
currently anticipated are: risks relating to the results of research and development activities, including those from our existing and
any new pipeline assets; early-stage clinical data may not be predictive of results from larger or later-stage studies; our need for substantial
additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern;
our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our
product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access
to LYMPHIR; our ability to maintain Nasdaq&rsquo;s continued listing standards; our ability to use the latest technology to support our
commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance
on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers
and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory
compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations;
our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements
and relationships; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government
regulation; as well as other risks described in our Securities and Exchange Commission (&ldquo;SEC&rdquo;) filings. These risks have been
and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees
of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business
are described in detail in our SEC filings which are available on the SEC&rsquo;s website at www.sec.gov, including in Citius Oncology&rsquo;s
Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements
speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions
to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">REFERENCES:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><B>American Cancer Society.</B> <I>Cancer Facts &amp; Figures 2026</I> (projected). Atlanta: American Cancer Society; 2026. https://www.cancer.org/cancer/types/endometrial-cancer/about/key-statistics.html</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><B>National Cancer Institute.</B> Surveillance, Epidemiology, and End Results Program (SEER). <I>Cancer Stat Facts: Uterine and Ovarian
Cancer. </I>https://seer.cancer.gov/statfacts/html/ovary.html</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">KEYTRUDA<SUP>&reg;</SUP> is a registered trademark
of Merck &amp; Co., Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LYMPHIR&trade; (denileukin diftitox-cxdl)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>INDICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LYMPHIR is an IL2-receptor-directed cytotoxin
indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic
therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IMPORTANT SAFETY INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>BOXED WARNING: CAPILLARY LEAK SYNDROME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Capillary leak syndrome (CLS), including life-threatening
or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold
LYMPHIR until CLS resolves, or permanently discontinue based on severity.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WARNINGS AND PRECAUTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Capillary Leak Syndrome</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LYMPHIR can cause capillary leak syndrome (CLS),
including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following
symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin &lt;3 g/dL. These symptoms were not required to occur
simultaneously to be characterized as capillary leak syndrome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As defined, CLS occurred in 27% of patients in
the pooled population across 3 clinical trials, including 8% with Grade 3. There was one (0.8%) fatal occurrence of CLS. Of the patients
with CLS, 22% had recurrence. The majority of CLS events (81%) occurred within the first 2 cycles of treatment. The median time to onset
from Cycle 1, Day 1 was 6.5 days (range: 1 to 77), the median duration of CLS was 14 days (range: 2 to 40), and 75% of patients had resolution.
The most common symptoms included edema, hypoalbuminemia, and hypotension. Pleural effusion, pericardial effusion, and dehydration also
occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regularly assess patients for weight gain, new
onset or worsening of edema, dyspnea, and hypotension (including orthostatic changes). Monitor serum albumin levels prior to the initiation
of each cycle of therapy and more often as clinically indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Withhold, reduce dose, or permanently discontinue
based on severity. If LYMPHIR is withheld, resume LYMPHIR following resolution of CLS and when serum albumin is greater than or equal
to 3 g/dL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Visual Impairment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LYMPHIR can cause serious visual impairment, including
changes in visual acuity and color vision. In the pooled population across 3 clinical trials, visual impairment occurred in 9%, with Grade
1 in 8% and Grade 2 in 1%. The most commonly reported symptom was blurred vision. Of the patients with visual impairment, 67% had resolution
of their visual impairment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Perform baseline ophthalmic examination and monitor
as clinically indicated. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision,
or blurred vision, refer for ophthalmologic evaluation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Withhold LYMPHIR until visual impairment resolves
or permanently discontinue based on severity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Infusion-Related Reactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LYMPHIR can cause serious infusion-related reactions.
Infusion-related reactions were reported in 69% of patients in the pooled population across 3 clinical trials of patients who received
LYMPHIR, with Grade 3 infusion-related reactions in 3.4%. Eighty-three percent of infusion-related reactions occurred in Cycles 1 and
2. The most common symptoms included nausea, fatigue, chills, musculoskeletal pain, vomiting, fever, and arthralgia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Premedicate patients for the first three cycles
prior to starting a LYMPHIR infusion. Monitor patients frequently during infusion. For Grade 2 or higher infusion reactions, premedicate
at least 30 minutes prior to each subsequent infusion with a systemic steroid for at least 3 cycles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interrupt or discontinue LYMPHIR based on severity.
Institute appropriate medical management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Hepatotoxicity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LYMPHIR can cause hepatotoxicity. In the pooled
safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients,
with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median time to onset was 8 days (range: 1 to 15 days); median time to
resolution was 15 days (range: 7 to 50 days); all cases of Grade 3 ALT or AST elevations resolved. Elevated total bilirubin occurred in
5% of patients, with Grade 3 occurring in 0.9%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Monitor liver enzymes and bilirubin at baseline
and during treatment as clinically indicated. Withhold, reduce dose, or permanently discontinue LYMPHIR based on severity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Embryo-Fetal Toxicity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on its mechanism of action, LYMPHIR can
cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to the
initiation of LYMPHIR. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective
contraception during treatment and for 7 days following the last dose of LYMPHIR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ADVERSE REACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The most common adverse reactions (&ge;20%), including
laboratory abnormalities, are increased transaminases, albumin decreased, nausea, edema, hemoglobin decreased, fatigue, musculoskeletal
pain, rash, chills, constipation, pyrexia, and capillary leak syndrome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>USE IN SPECIFIC POPULATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pregnancy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Risk Summary</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on its mechanism of action, LYMPHIR can
cause fetal harm when administered to a pregnant woman. There are no available data on the use of LYMPHIR in pregnant women to evaluate
for a drug-associated risk. No animal reproductive and developmental toxicity studies have been conducted with denileukin diftitox.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Denileukin diftitox-cxdl causes depletion of regulatory
T lymphocytes (Treg), immune activation, and capillary leak syndrome, compromising pregnancy maintenance. Advise pregnant women of the
potential risk to a fetus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the U.S. general population, the estimated
background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lactation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Risk Summary</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No data are available regarding the presence of
denileukin diftitox-cxdl in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious
adverse reactions in breastfed children, advise women not to breastfeed during treatment with LYMPHIR and for 7 days after the last dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Females and Males of Reproductive Potential</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on its mechanism of action, LYMPHIR can
cause fetal harm when administered to a pregnant woman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Pregnancy Testing</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Verify the pregnancy status of females of reproductive
potential prior to initiating LYMPHIR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Contraception</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Females</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advise females of reproductive potential to use
effective contraception during treatment with LYMPHIR and for 7 days after the last dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Infertility</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Males</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on findings in rats, male fertility may
be compromised by treatment with LYMPHIR. The reversibility of the effect on fertility is unknown.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Pediatric Use</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Safety and effectiveness of LYMPHIR in pediatric
patients have not been established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Geriatric Use</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Of the 69 patients with Stage I-III r/r CTCL who
received LYMPHIR, 34 patients (49%) were 65 years of age and older and 10 patients (14%) were 75 years of age and older. Clinical studies
of LYMPHIR did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from
younger adult patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You may report side effects to the FDA at 1-800-FDA-1088
or www.fda.gov/medwatch. You may also report side effects to Citius Oncology at 1-844-459-6744.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please read Important Safety Information and full
Prescribing Information, including Boxed WARNING, for LYMPHIR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ilanit Allen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ir@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">908-967-6677 x113</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">STiR-communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Greg Salsburg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Greg@STiR-communications.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea028066301_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028066301_ex99-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !K ,$# 2(  A$! Q$!_\0
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MYA6&*- 'D5I(U?X6_P"(@G_@C3_T?_\ !#_P)\2__,]7RC_P<C?\$J_VEO\
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M1%M8FT:QMOED>]92RJ ?Z-/PM^+OPL^-_@_3_B#\'/B-X)^*7@;5=PT[Q;X
M\3:/XL\/W;JJ.\46JZ)=WEF9HTDC:2!I1-&LB%T4.I/HE?AO_P &]'_!.WXC
M_P#!-+_@G/X;^"7QLTK3="^./C3XH?$3XM_%C1M(UFV\0:?I.O:]=:=X5\/Z
M=!K-A/<Z9?O;> O!GA(W4^EROIYOI+I8);C:UU/^Y% !1110 4444 ?RC?\
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MXH _U-O^"[?_ "AZ_P""B'_9L_CK_P!%VE?Y9?\ P0N_Y2_?\$\O^SFO /\
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M5AK6BWHT[38[B:"&6[DMK2X>&%ID,K1^6A+LJD _RCO^"(7_ "EU_P""=O\
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M$5LY'O\ D<?GC%?DM^T9_P %"? ?[!G[)W[..IZKX>NO'GQ#\>_"WP19^!O
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MK7PT<9#V5&OB(+"U(J=*M4J4(5(4XUH-2I.=N9--\J:;_J$R,X]L_P"?Z_\
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M[RK@*6'7M81GB(X>E0IU*E&+E&56//&:YH1E%J#E?E:;Y<CR#,\NS+PXIXK
MXI>PPV<8C&-X:K.G@YXS$8VO1IXJ<*<Z5"IR.E+DJSA*,I\K7,FE^:?_  1S
M_P")?_P5ATS^SK>*(V%O^U.NGVD$*QV\0M= \6+:6T%O$JQQP1K%%#%!$JHD
M:K'&JJ HW?\ @C-I%IXP_P""IVA7_B4O)J&EI\>O&5J9)-KOXDMA>VL;/YNY
MW:.+5]08QY\SY,Y_=''TG_P2M_8E_:\^$/\ P4WTCXK?%']G7XF^ _AI!<_M
M"O-XW\0Z9I]OH,:>)=.\1Q>'R\\&J7$P&L275LEEBW.\SH'"#)'(_%+]BW]L
M_P#X)T?MZG]H;]GOX):]\;_A[;>.O$WC#P!>Z!I^J>)-*N= \:C55U'P-XUC
MTVXCUW2=;L8=1NXDO"K07,EI:ZC;RS0%X&]'%8O!XG%9K@J6.PBKX_AK!T,-
M4>)HJE.O!8GVE%XAU'3A4O44I0G.,K2;:T9Y. RW,\#E_#F9XC*\PEA<HXVS
M'%8^C' XJ5>EA:RP/LL5'"JC&M4H\U&24X491;A&*DKIG[!?$G]C[_@F_KO[
M?5O\:O%O[1MMX>_:A7XM_#WQ6GPKB^*/A72GE\>Z/;>'4\,:.W@^2V_M>2;7
M([+2II+(2_:M1:^:2-S]I4U^$?Q%L[;XC_\ !=&XT3QE%)<:9J7[:WAC0[RV
M>XFB/]FZ-<Z4FG0)-(S/#&GV"U=47;']Y44+)BOJ3]CW]B_]L/\ ;!_X*&VO
M[:O[2'PCU3X->$-%^)NF_%?76\2:?/X?;5=7\*0VD/@[P9X+T>_DFUF_M+!]
M)TJ'4=6O4BMXK*PN2]R]]<V\3ZG_  5._P""?'[3W@;]LB?]L;]G+X?Z_P#%
M#PUXH\5>%?B1<P^%K9]:UOP;\0O#<FG"\M]:T*":#4I_#NL3Z99SP7FFATB2
MZN+.5X9E$QX<MJ8?!9@\NKYW'%8BKPW4P4*E:OAWAL#BIZQP5#$TVJ?)&.JE
M.HW>G%<W,U!^OG5+%YID_P#;.#X7J9?@\/QI1S*K2P^%Q:QV:X"DO?S3%8&K
M"593FU*$O9T5%>VG+E<%*1Y=_P '#]I;Q?MC_#BXA@CCN+S]GS0Y+B9(P'GD
M@\;^-X86F<<NT<2+&A;.V-0H[8^?/^"MFJZAKWQ5_9FUW5KJ34-5UO\ 8;_9
MVU?5-0FV>9>ZAJ.CZK=7MW)Y:I'YES<323/L54+OE55< >[^//V>?^"@'_!6
M#]K'PQXU^+'[/VL? CPIIVC^%_".OZYK6EZKX?\ "7@_P5I%[<ZEK#Z:_B">
M?6->\1ZO<:AJES8V%G'*!<7%ND[V]I;23GVW_@L7^Q)^TS\4OVGO"&I? 7]G
M[XA?$3P!X;^ W@+P59ZUX2TO3IM(M;GP]?\ B&$:2IEU"R$4]E8R63-#% L2
M)-&$..!Z&6XO"8*MPUE^(QN"^L8'*\T^LRCB\/.C1E7C3C3I2Q"J>Q<ZBNX0
M51-J%^5*U_-S; YAFE#C3.,)EN8O!9KGN3?4*<\!BZ>)Q,,/.LZU>.$=#VZI
MP2]ZI*ER1=11<^;F2^:O^"T]Y=2>*_V.;1II#;VO[$O@":VAW_)#).9_/EC'
M\+OY<8=N68(G("C'W=_P65TO3;/_ ()_?L'BUM;*S^PW/@FWLH+2VM[=(K>Y
M^#+O<0V\<,:"*%GBADECB"QNZ([JS(I'3_\ !4[_ ()V?&[X[_![]F'XL?";
MP;J/BKQ]\*_@EX7^&?Q(^&5NUK%XJDTF'1=.O(KK1+.5T35-4T769-3T[5M+
MBNS<M#);2V44ZP7++\!_%VW_ ."FG[;GPX_9V_9G\0_LL>+M/L_@[#;66G>)
MKSPKJ/AK^WKVUTI/"^F^(?&6OZ_<QZ3HEII>A,+2[6R\F"XN)IKUX7(MX8>7
M+JV&Q6&X7KT\;@J5/)L7F$LPC6Q5&A4I1FL6HS5.I.$ZJGSQE%PC/FC*Z=ER
MGIYM0QF!Q_&V%K9=F->MQ%@<JAE%3#X'$8BE6G">7SE3E6ITIPI2I.G.,XU'
M!QE3<&HWBUQ?Q\U35)?^"3O[ 5A,]PEA_P +C^.T(CDF,T5W#93:K+93*&RT
M,=O->7L,,(*A661MI#U^@T7A'P9%_P &^3W3V.GV]S</;^,GN%\EII?&\GQA
MMK!;\2R>:T&HW5HJ:>_DF*5K.1[8;89G1OJ+]H7_ ()CW%]_P34^$'[-'AWQ
M/X9C^,7P8GM_&.A:EK^LVN@^'O%7C?5I=1OO'7AZ+4K][2VMK74#K-Y:Z-J-
MW$S0QZ;8270B$T]PGXR^-?V;_P#@HS\)OV,_B#X-^*5S9> ?V3O ^I:;XZO-
M!O?$7A;6%\3^)]:\3:=I6F:+X;NM EU'4[^"?7KN/5I;22[AT*SN;8W<C?:Y
M+:*2L/C,#FU##0H8_#86I0XMJX_V5><Z4\30JXRI.C["$8.56=95(J$4FU)R
M4U32;<XS 9ED6+QE7%95B\;2QG 5'+/:X>G"M2P>)HY?3IU_K=3F:H4\.Z,^
M>;:?*HNG[6Z2_27_ ((@> --^*W[&_[7WPUUB*";3O'?BZ[\*W"W*EX4_MKX
M<VUC#/(D95C]FGFBN  <[HAC-?E)^R;\6]1_9P\%_P#!0SX4ZWJMQH^N:]\!
MO$'@W3M+GE2!M1\5^'_&5MX2U6)8;B%XGOY?#>N:H1"[1S/:BX2U5I 63]F_
M^#>=L_ ?X_CN/C!I.1WY\&Z;C.>@QQP.GTK\=/\ @KE\*H?A1^WA\88M.\@6
M/Q%&C?%.Q@@GCFD2Z\8V9;64NXXG+6\TWB.QU6XBMKA8Y3:3VTX5H9X99.C
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M]/04M%%D FT>_P"9_/KU]Z" 1@\CTR:6B@#XF_;Q_8TT+]MKX+#X9WGBN_\
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K$B1Q(L<<:JB(@"HB(H5%51@*JJH50    !Q3Z**\4^E"BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ctor-20260310.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 86o5s7xRiXhun8uDb31cWaKN+aPty5BxOZkxsmx5HXmanycrAufe1CUx793GAZUA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:CTOR="http://citiusonc.com/20260310" elementFormDefault="qualified" targetNamespace="http://citiusonc.com/20260310">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://citiusonc.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ctor-20260310_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ctor-20260310_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ctor-20260310_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ctor-20260310_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="ctor-20260310.xsd#Cover" roleURI="http://citiusonc.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://citiusonc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 10, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 10,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Citius Oncology, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001851484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">99-4362660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Commerce Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">1st Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranford<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">967-6677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CTOR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ea0280663-8k_citius.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://citiusonc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ctor-20260310.xsd</File>
    <File>ctor-20260310_lab.xml</File>
    <File>ctor-20260310_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0280663-8k_citius.htm">ea0280663-8k_citius.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0280663-8k_citius.htm": {
   "nsprefix": "CTOR",
   "nsuri": "http://citiusonc.com/20260310",
   "dts": {
    "schema": {
     "local": [
      "ctor-20260310.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ctor-20260310_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ctor-20260310_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0280663-8k_citius.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://citiusonc.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0280663-8k_citius.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0280663-8k_citius.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://citiusonc.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001213900-26-025464-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-025464-xbrl.zip
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M%R872]TD_W!Q!NUSA@I'HJD43J;B#*#-SP#R$UI^VJ;TDTH,K'"W]A9.+,^
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M3GR)I/E'8,77A=V14?E_4$L#!!0    ( '!):ERB.A+ OR   %Z@   5
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M8NMZ/-ZFAZ4X>%LT+X335$5J!KXT-^Y_&+=@E!DQAC2%NB\Z;0%OIF2H%\-
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MMXI\]HS]D,XB"P->\,YDC/^'>[C"-#6:/Z;X9O+!WE?SP95S@NUN#9W!R)R
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M,S$P+GAS9%!+ 0(4 Q0    ( '!):EQ5&@"@_0H  '^&   5
M  "  5D#  !C=&]R+3(P,C8P,S$P7VQA8BYX;6Q02P$"% ,4    " !P26I<
M8EX;PEP'  #65P  %0              @ &)#@  8W1O<BTR,#(V,#,Q,%]P
M<F4N>&UL4$L! A0#%     @ <$EJ7#+$PFL#$@  $EP  !<
M ( !&!8  &5A,#(X,#8V,RTX:U]C:71I=7,N:'1M4$L! A0#%     @ <$EJ
M7*(Z$L"_(   7J   !4              ( !4"@  &5A,#(X,#8V,S Q97@Y
=.2TQ+FAT;5!+!08     !0 % $T!  !"20     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ea0280663-8k_citius_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ctor-20260310.xsd" xlink:type="simple"/>
    <context id="AsOf2026-03-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001851484</identifier>
        </entity>
        <period>
            <startDate>2026-03-10</startDate>
            <endDate>2026-03-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-03-10" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-03-10" id="Fact000004">0001851484</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-03-10" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-03-10" id="Fact000010">2026-03-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-03-10" id="Fact000011">Citius Oncology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-03-10" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-03-10" id="Fact000013">001-41534</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-03-10" id="Fact000014">99-4362660</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-03-10" id="Fact000015">11 Commerce Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2026-03-10" id="Fact000016">1st Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-03-10" id="Fact000017">Cranford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-03-10" id="Fact000018">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-03-10" id="Fact000019">07016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-03-10" id="Fact000020">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-03-10" id="Fact000021">967-6677</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-03-10" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-03-10" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-03-10" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-03-10" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-03-10" id="Fact000026">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-03-10" id="Fact000027">CTOR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-03-10" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-03-10" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2026-03-10" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
